U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week
U.S. Renal Care presented VOICE trial results at ASN Kidney Week showing vadadustat (Akebia's Vafseo) achieved noninferiority and superiority versus an ESA on a composite of all-cause mortality and hospitalization (win odds 1.16, p=0.0016) in 2,116 dialysis patients. Hospitalization rates were 10% lower with vadadustat, serious adverse events were reduced, and hemoglobin control was meaningfully more stable, with 57-64% reductions in high-hemoglobin excursions. The data support vadadustat positioning as a potential new standard of care, a positive catalyst for Vafseo U.S.
Key figures
- Drug Name
- Vafseo (vadadustat)
- Phase Of Trial
- Phase 3b/real-world (VOICE, randomized noninferiority trial)
- Win odds
- 1.16
- Win odds ci
- 95% CI 1.06-1.28
- Mortality irr
- 1
- P value primary
- 0.0016
- Patients enrolled
- 2116
- Hg B excursion reduction
- 64% (HgB>12), 57% (HgB>13), 61% (HgB>14)
- Esa rescue odds reduction
- 28%
- Hospitalization rate reduction
- 10% (IRR 0.90, 95% CI 0.82-0.99)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.